Company Overview and News

 
Closing Bell: Sensex up over 300 pts, midcaps underperform; IT zooms, ONGC dips

15h moneycontrol
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.

 
Market Update: SBI top gainer on Nifty, up 3% despite poor Q4; PC Jeweller zooms 16%

2018-05-22 moneycontrol
The market continues to trade on a positive note on Tuesday afternoon, with the Nifty up 11 points at 10,523 and the Sensex up 30 points at 34,646.

 
Market Update: 154 stocks hit new 52-week lows; RCom, JP Associates jump 4-8%

2018-05-22 moneycontrol
The market was trading on a negative note on Tuesday morning, with the Nifty down 19 points at 10,496 and the Sensex down 51 points at 34,569.

 
Market Update: 231 stocks hit new 52-week lows as midcaps bleed; JP Associates tanks 15%

2018-05-21 moneycontrol
The market was trading flat on Monday afternoon, with the Nifty down 59 points at 10,536 and the Sensex down 152 points at 34,695.

 
Market update: PSU banks outperform led by SBI, BoI; HUL, TCS hits new 52-week highs

2018-05-21 moneycontrol
The market is trading flat, with the Nifty up 16 points at 10,613. The Sensex is up 61 points at 34,909.

 
Ajanta Pharma Limited - Updates

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Ajanta Pharma Limited - Allotment of ESOP/ESPS

2018-05-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Market Update: CNX Pharma down as Sun Pharma slides 5%; telecom stocks tumble as Idea falls 12%

2018-05-11 moneycontrol
The equity market continued to trade on a positive note on Friday afternoon, with the Nifty trading 70 points up at 10,787 and the Sensex trading 215 points higher at 35,461.

 
Market update: Midcaps gain led by HPCL, Biocon; Idea falls 7%, Bharti Airtel sheds 4%

2018-05-11 moneycontrol
The equity market was trading on a positive note on Friday afternoon. The Nifty is up 33 points at 10,750 levels and the Sensex is trading 79 points higher, or up 0.23 percent.

 
Market update: 104 stocks hit new 52-week lows; PNB down 3%, Asian Paints top gainer at 5%

2018-05-11 moneycontrol
The equity market was trading on a positive note on Friday morning. The Nifty is up 22 points at 10,739 levels and the Sensex is trading 51 points higher, or 0.15 percent.

 
Natco Pharma: Tonic for growth

2018-05-06 premium.thehindubusinessline
The past few years have been docile for Indian pharma companies. Regulatory tightening, coupled with multiple headwinds in the key markets, have not augured well for Indian drug makers.

 
Market Update: FMCG stocks trade weak as ITC, Emami fall 2-3%; Sun Pharma top loser, PC Jeweller up 21%

2018-05-04 moneycontrol
The Indian equity market extended loses and was trading on a negative note on Friday afternoon with the Nifty falling 54 points was trading at 10,625 while the Sensex was down 177 points or 0.51 percent.

 
Market Update: 88 stocks hit new 52-week low; Sun Pharma, TVS Motor down 2-3%, PC Jeweller zooms 22%

2018-05-04 moneycontrol
The Indian equity market extended loses was trading on a negative note on Friday afternoon with the Nifty falling 54 points was trading at 10,624 while the Sensex was down 179 points or 0.51 percent.

 
Ajanta Pharma Limited - AGM/Book Closure

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Ajanta Pharma Limited - Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...